NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,429.85 mln
Float52.49 mln
Earnings Date07/30/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-6.99
Highly reliable
1-Year Forecast
119
Attractive
Relative Strength
16
/ 100
Significantly lagging
Debt / Equity
0.01
Debt-free
ROE
-17.53
Negative
Business Description
Protagonist Therapeutics is a US-based drug discovery and development company focused on creating novel treatments for blood disorders, skin conditions, and obesity. Its most advanced programs include Rusfertide, an injectable treatment in late-stage trials for the rare blood disorder polycythemia vera, and Icotyde, an oral peptide therapy for moderate-to-severe plaque psoriasis. The company has several additional candidates in earlier stages of development targeting conditions such as atopic dermatitis, asthma, and obesity. Founded in 2006 and based in Newark, California, Protagonist has built its pipeline around peptide-based medicines designed to mimic or block naturally occurring proteins in the body.